Azetidinones as vasopressin V1a antagonists

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• The vasopressin V1a receptor is a key target for various physiological processes.
• Ketoconazole, a known antagonist of the luteinizing hormone releasing hormone receptor, served as a structural reference.
• Azetidinone LY307174 (1) was initially identified as a screening lead with moderate affinity for the vasopressin V1a receptor (IC50 = 45 nM).

Purpose of the Study:

• To explore structure-activity relationships (SAR) of azetidinone derivatives.
• To optimize compounds for enhanced affinity at the vasopressin V1a receptor.
• To improve pharmacokinetic properties, particularly brain penetration after oral dosing.

Main Methods:

• Molecular similarity analysis was used to identify the initial azetidinone lead.
• Systematic structural modifications of the azetidinone scaffold were performed.
• In vitro assays were conducted to determine receptor binding affinity (Ki values).
• In vivo pharmacokinetic studies assessed brain levels following oral administration.

Main Results:

• Optimization efforts led to compounds with significantly improved vasopressin V1a receptor affinity, achieving Ki values below 1 nM.
• The optimized compounds demonstrated substantial brain penetration, with levels approximately 100-fold higher than their receptor affinities after oral dosing.
• Structure-activity relationship studies elucidated key molecular features contributing to both receptor affinity and favorable pharmacokinetics.

Conclusions:

• Azetidinone derivatives can be effectively optimized into potent vasopressin V1a receptor antagonists.
• The developed compounds possess promising characteristics for potential therapeutic applications targeting the vasopressin V1a receptor.
• High brain levels achieved after oral administration suggest good central nervous system bioavailability.